Paola Zaratin PhD

Paola joined Italian MS Society on February 2010 where she currently holds the position of Director of
Scientific Research on Research Programme in Biomedical Research, Research in Public Health, Research in Rehabilitation and Communication in Scientific Research. Paola has 29 years of experience working in Neuroscience Research and in the last 18 years in the field of Multiple Sclerosis. She also has 21 years of experience working in Drug Discovery and Development in the Neuroscience area. She is author of more than 60 original papers, published on international peer reviewed journals and 6 patents.

Bridging scientific results to people affected by neurological diseases (translational and advocacy research) has always been Paola’s guiding research and professional interest. She has experience in leading national and international multidisciplinary and multistakeholder teams and developing collaborative networks in Public, Profit and non-Profit sectors.

Paola is currently member of the International Medical and Scientific Board of the International Multiple Sclerosis Federation. She is also member of the Scientific Committee and of the Industry Forum of the International Progressive Multiple Sclerosis Alliance whose mission is to ‘to expedite the development of effective disease modifying and symptom management therapies for progressive forms of multiple sclerosis’ (Reference:Fox et al.,“Setting a research agenda for progressive multiple sclerosis: The international collaborative on progressive MS”. Multiple Sclerosis Journal 2012). As director of scientific research of the Italian MS Society Foundation, Paola has developed a management model for the Italian MS Society portfolio
that also allows effective programs of technology transfer aimed at developing new therapies (pharmacological and rehabilitation) for people with MS. The above model has attracted public and Industry funding (joint patent application (UNIMI-FISM) covering 3 families of ligands active on GPR17 to be further developed as new re-myelinating agents; Nonprofit foundations spur translational research. Zaratin et al., Trends Pharmacol Sci. 2014; Zaratin et al., Progressive MS Alliance Industry Forum: Maximizing Collective Impact To Enable Drug Development. Trends Pharmacol Sci. 2016). Paola will coordinate, as Project Coordinator and LEAR, the H2020 SWAFS-05-2017 MULTI-ACT three years project, “MULTI-ACT: A Collective Research Impact Framework and multi-variate models to foster the true engagement of actors and stakeholders in Health Research and Innovation” which has been granted by The European Commission in 2017.